|
|
BMS-599626 An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|
|